This Article Full Text Full Text (PDF) All Versions of this Article: 48/1/1    most recent 01.HYP.0000226145.49783.a9v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sawicki, P. T. Articles by McGauran, N. Search for Related Content PubMed PubMed Citation Articles by Sawicki, P. T. Articles by McGauran, N. Related Collections Cardiovascular Pharmacology Clinical Studies

(Hypertension. 2006;48:1.)
© 2006 American Heart Association, Inc.

Brief Reviews

Have ALLHAT, ANBP2, ASCOT-BPLA, and So Forth Improved Our Knowledge About Better Hypertension Care?

From the Institute for Quality and Efficiency in Health Care, Cologne, Germany.

Correspondence to Peter T. Sawicki, Institute for Quality and Efficiency in Health Care, Dillenburger Str 27, D-51105 Cologne, Germany. E-mail annette.ress@iqwig.de

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
One of the major milestones in medicine during the last 40 years has been strong evidence from well-designed clinical trials showing that blood pressure–lowering interventions reduce hypertension-related morbidity and mortality.¹ Whereas initially these results were in most cases achieved with high-dose thiazide diuretics, subsequent research demonstrated that dose reduction, including combination with potassium-sparing agents, is effective and decreases the risk of adverse effects.^2,3 Since then, several new antihypertensive agents have been developed, but meta-analyses have not indicated a superior beneficial effect of these agents over conventional ones.^4,5 However, many hypertension experts do not recommend thiazide diuretics as first-line treatment for hypertension, and guidelines are inconsistent.^6–8

There were 2 major reasons for this failure to transform sound scientific evidence into practice. Firstly, potential thiazide-induced metabolic effects (eg, a transient increase in serum cholesterol and a serum potassium–dependent slight increase in blood glucose levels) were thought to be responsible for the so-called shortfall in the reduction in cardiovascular events (the gap between the epidemiologically estimated decrease in the risk of hypertension-related events and the magnitude of the decrease actually achieved in intervention trials).⁹ Second, protective effects beyond the blood pressure–lowering effect were attributed to newer agents, which include -blockers, calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), and, more recently, angiotensin receptor blockers. Despite the fact that this theory was not confirmed in head-to-head trials, the vigorous marketing of these agents, combined with a campaign against the use of diuretics, changed prescription habits worldwide.¹⁰ This controversy was the reason for the largest . . . [Full Text of this Article]

This article has been cited by other articles:

				M. Davidson, S. Galderisi, M. Weiser, N. Werbeloff, W. W. Fleischhacker, R. S. Keefe, H. Boter, I. P.M. Keet, D. Prelipceanu, J. K. Rybakowski, et al. Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST) Am J Psychiatry, June 1, 2009; 166(6): 675 - 682. [Abstract] [Full Text] [PDF]

				A. Boneparth and J. T. Flynn Evaluation and Treatment of Hypertension in General Pediatric Practice Clinical Pediatrics, January 1, 2009; 48(1): 44 - 49. [Abstract] [PDF]

				K. D. Pendergrass, N. T. Pirro, B. M. Westwood, C. M. Ferrario, K. B. Brosnihan, and M. C. Chappell Sex differences in circulating and renal angiotensins of hypertensive mRen(2).Lewis but not normotensive Lewis rats Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H10 - H20. [Abstract] [Full Text] [PDF]

				B. Williams The Year in Hypertension J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1803 - 1817. [Full Text] [PDF]

				K. R. Pechman, D. P. Basile, H. Lund, and D. L. Mattson Immune suppression blocks sodium-sensitive hypertension following recovery from ischemic acute renal failure Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1234 - R1239. [Abstract] [Full Text] [PDF]

				L. Bankir, M. Bochud, M. Maillard, P. Bovet, A. Gabriel, and M. Burnier Nighttime Blood Pressure and Nocturnal Dipping Are Associated With Daytime Urinary Sodium Excretion in African Subjects Hypertension, April 1, 2008; 51(4): 891 - 898. [Abstract] [Full Text] [PDF]

				M. Marre and A. Leye Effects of perindopril in hypertensive patients with or without type 2 diabetes mellitus, and with altered insulin sensitivity Diabetes and Vascular Disease Research, September 1, 2007; 4(3): 163 - 173. [Abstract] [PDF]

				K. R. Spurgeon-Pechman, D. L. Donohoe, D. L. Mattson, H. Lund, L. James, and D. P. Basile Recovery from acute renal failure predisposes hypertension and secondary renal disease in response to elevated sodium Am J Physiol Renal Physiol, July 1, 2007; 293(1): F269 - F278. [Abstract] [Full Text] [PDF]

				T. E. Lohmeier, T. M. Dwyer, E. D. Irwin, M. A. Rossing, and R. S. Kieval Prolonged Activation of the Baroreflex Abolishes Obesity-Induced Hypertension Hypertension, June 1, 2007; 49(6): 1307 - 1314. [Abstract] [Full Text] [PDF]

				T. L. Reudelhuber, K. E. Bernstein, and P. Delafontaine Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy?: Time for Another Look Hypertension, June 1, 2007; 49(6): 1196 - 1201. [Full Text] [PDF]

				P. Verdecchia, F. Angeli, C. Borgioni, R. Gattobigio, and G. Reboldi Ambulatory Blood Pressure and Cardiovascular Outcome in Relation to Perceived Sleep Deprivation Hypertension, April 1, 2007; 49(4): 777 - 783. [Abstract] [Full Text] [PDF]

				C. M. Boulanger, N. Amabile, A. P. Guerin, B. Pannier, A. S. Leroyer, Z. Mallat, C. Nguyen, A. Tedgui, and G. M. London In Vivo Shear Stress Determines Circulating Levels of Endothelial Microparticles in End-Stage Renal Disease Hypertension, April 1, 2007; 49(4): 902 - 908. [Abstract] [Full Text] [PDF]

				N. M. Kaplan Clinical Trials for Hypertension: Expectations Fulfilled and Unfulfilled Hypertension, February 1, 2007; 49(2): 257 - 259. [Full Text] [PDF]

				F. Persson, P. Rossing, P. Hovind, C. D.A. Stehouwer, C. Schalkwijk, L. Tarnow, and H.-H. Parving Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria: An IRMA 2 Substudy Diabetes, December 1, 2006; 55(12): 3550 - 3555. [Abstract] [Full Text] [PDF]